The significance of endothelial heterogeneity in thrombosis and hemostasis

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 3, 2010, Pages 286-300

  Kwaan, Hau C ^a   Samama, Meyer Michel ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HÔTEL DIEU   (France)

Author keywords

Endothelium; Hemorrhage; Hemostasis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ASPARAGINASE; AUTOANTIBODY; CYTARABINE; DACTINOMYCIN; DEFIBROTIDE; FIBRINOLYTIC AGENT; FLICE INHIBITORY PROTEIN; GEMTUZUMAB OZOGAMICIN; GONADOTROPIN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1; JANUS KINASE 2; LIPOCORTIN 2; MITHRAMYCIN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; RETINOIC ACID; SHIGA TOXIN; TIOGUANINE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URETHAN; UROKINASE RECEPTOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL HEMORRHAGE; APOPTOSIS; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN VEIN; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CEREBRAL SINUS THROMBOSIS; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; FIBRINOLYTIC THERAPY; GENE EXPRESSION; GENE MUTATION; HEART INFARCTION; HEMARTHROSIS; HEMOLYTIC UREMIC SYNDROME; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; IMMOBILIZATION; LIVER VEIN OBSTRUCTION; LUNG EMBOLISM; LUNG HEMORRHAGE; MEMBRANE MICROPARTICLE; MICROVASCULATURE; MORPHOLOGY; MYELOPROLIFERATIVE DISORDER; OCCLUSIVE CEREBROVASCULAR DISEASE; OVARY HYPERSTIMULATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN C DEFICIENCY; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; SINUSOIDAL OBSTRUCTION SYNDROME; SPLANCHNIC VEIN THROMBOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE NECROSIS; VEIN THROMBOSIS;

ANIMALS; ENDOTHELIUM, VASCULAR; HEMORRHAGE; HEMOSTASIS; HUMANS; PHENOTYPE; THROMBOSIS;

EID: 77953273217     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1253451     Document Type: Review

References (161)

1. His W. Die Häute und Höhlen des Körpers. Basel, Switzerland Schwighauser 1865
2. Rosenberg R D., Aird W C. Vascular-bedspecific hemostasis and hypercoagulable states. N Engl J Med 1999 340 (20) 1555-1564
3. Aird W C. Endothelial cell heterogeneity. Crit Care Med 2003 31 (4, suppl) S221-S230
4. Aird W C. Mechanisms of endothelial cell heterogeneity in health and disease. Circ Res 2006 98 (2) 159-162
5. Aird W C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007 100 (2) 158-173
6. Aird W C. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007 100 (2) 174-190
7. Aird W C. Molecular heterogeneity of tumor endothelium. Cell Tissue Res 2009 335 (1) 271-281
8. Aird W C. Vascular bed-specific thrombosis. J Thromb Haemost 2007 5 (suppl 1) 283-291
9. Pries A R., Kuebler W M. Normal endothelium. Handb Exp Pharmacol 2006 (176 Pt 1) 1-40
10. Bennett H S., Luft J H., Hampton J C. Morphological classifications of vertebrate blood capillaries. Am J Physiol 1959 196 (2) 381-390
11. Tse D, Stan R V. Morphological heterogeneity of endothelium. Semin Thromb Hemost 2010 36 (3) 236-245
12. Aird W C. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005 3 (7) 1392-1406
13. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007 44 (2) 62-69
14. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005 352 (17) 1791-1798
15. Ferro J M., Canhão P, Stam J, Bousser M G., Barinagarrementeria F, ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004 35 (3) 664-670
16. Athale U H., Chan A K. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003 111 (3) 125-131
17. Payne J H., Vora A J. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007 138 (4) 430-445
18. Caruso V, Iacoviello L, Di Castelnuovo A et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006 108 (7) 2216-2222
19. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati M B. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007 5 (3) 621-623
20. Athale U H., Chan A K. Thrombosis in children with acute lymphoblastic leukemia. Part II Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003 111 (45) 199-212
21. Zakarija A, Kwaan H C. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007 33 (4) 355-364
22. Athale U H., Chan A K. Thrombosis in children with acute lymphoblastic leukemia. Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res 2003 111 (6) 321-327
23. deVeber G, Andrew M, Adams C et al, Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl J Med 2001 345 (6) 417-423
24. Coutinho J M., Ferro J M., Canhão P et al. Cerebral venous and sinus thrombosis in women. Stroke 2009 40 (7) 2356-2361
25. Martinelli I, Taioli E, Palli D, Mannucci P M. Risk of cerebral vein thrombosis and oral contraceptives. Lancet 1998 352 (9124) 326
26. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci P M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998 338 (25) 1793-1797
27. Lanska D J., Kryscio R J. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000 31 (6) 1274-1282
28. Cantu C, Alonso E, Jara A et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke 2004 35 (8) 1790-1794
29. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci P M. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003 102 (4) 1363-1366
30. Warkentin T E., Greinacher A. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005 353 (3) 314-315
31. Hillmen P, Lewis S M., Bessler M, Luzzatto L, Dacie J V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995 333 (19) 1253-1258
32. Socié G, Mary J Y., de Gramont A et al, French Society of Haematology. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996 348 (9027) 573-577
33. Ziakas P D., Poulou L S., Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 2008 6 (4) 347-353
34. Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 1997 65 (3) 285-291
35. Ziakas P D., Poulou L S., Rokas G I., Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost 2007 5 (3) 642-645
36. De Stefano V, Fiorini A, Rossi E et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007 5 (4) 708-714
37. Arya R, Shehata H A., Patel R K. et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol 2001 115 (1) 153-155
38. Baumann P, Diedrich K. Thromboembolic complications associated with reproductive endocrinologic procedures. Hematol Oncol Clin North Am 2000 14 (2) 431-443
39. Mancuso A, De Vivo A, Fanara G, Di Leo R, Toscano A. Upper body venous thrombosis associated with ovarian stimulation: case report and review of the literature. Clin Exp Obstet Gynecol 2005 32 (3) 149-154
40. Loret de Mola J R., Kiwi R, Austin C, Goldfarb J M. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril 2000 73 (6) 1253-1256
41. Stewart J A., Hamilton P J., Murdoch A P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 1997 12 (10) 2167-2173
42. Chan W S., Ginsberg J S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ART behind the clot. J Thromb Haemost 2006 4 (8) 1673-1677
43. Nelson S M. Prophylaxis of VTE in womenduring assisted reproductive techniques. Thromb Res 2009 123 (suppl 3) S8-S15
44. Aune B, Oian P, Osterud B. Enhanced sensitivity of the extrinsic coagulation system during ovarian stimulation for in-vitro fertilization. Hum Reprod 1993 8 (9) 1349-1352
45. Lox C, Cañez M, DeLeon F, Dorsett J, Prien S. Hyperestrogenism induced by menotropins alone or in conjunction with luprolide acetate in in vitro fertilization cycles: the impact on hemostasis. Fertil Steril 1995 63 (3) 566-570
46. Bauersachs R M., Manolopoulos K, Hoppe I, Arin M J., Schleussner E. More on: the ART behind the clot: solving the mystery. J Thromb Haemost 2007 5 (2) 438-439
47. Paterson J C., McLachlin J. Precipitating factors in venous thrombosis. Surg Gynecol Obstet 1954 98 (1) 96-102
48. Bergan J J., Schmid-Schönbein G W., Smith P D., Nicolaides A N., Boisseau M R., Eklof B. Chronic venous disease. N Engl J Med 2006 355 (5) 488-498
49. Hamer J D., Malone P C., Silver I A. The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg 1981 68 (3) 166-170
50. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974 27 (7) 517-528
51. Kiladjian J J., Cervantes F, Leebeek F W. et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008 111 (10) 4922-4929
52. De Stefano V, Rossi E, Za T, Chiusolo P, Leone G. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal. Thromb Haemost 2008 99 (6) 1121
53. Kralovics R, Passamonti F, Buser A S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 352 (17) 1779-1790 (Pubitemid 40570926)
54. Wasserman L R., Balcerzak S P., Berk P D. et al. Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Physicians 1981 94 30-38
55. Marchioli R, Finazzi G, Landolfi R et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005 23 (10) 2224-2232
56. Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand 1962 172 513-523
57. Landolfi R, Marchioli R, Kutti J et al, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004 350 (2) 114-124 (Pubitemid 38056222)
58. Bellucci S, Michiels J J. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006 32 (4 Pt 2) 381-398
59. Cesar J M., de Miguel D, García Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol 2005 123 (5) 772-777
60. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005 33 (5) 523-530 (Pubitemid 40592168)
61. Di Nisio M, Barbui T, Di Gennaro L et al, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007 136 (2) 249-259
62. Gangat N, Wolanskyj A P., Schwager S M., Hanson C A., Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009 115 (24) 5740-5745
63. Brækkan S K., Mathiesen E B., Njølstad I, Wilsgaard T, Hansen J B. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica 2010 95 (2) 270-275
64. Bellucci S, Ignatova E, Jaillet N, Boffa M C. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993 70 (5) 736-742
65. Yoder M C., Mead L E., Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007 109 (5) 1801-1809
66. Patel R K., Lea N C., Heneghan M A. et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006 130 (7) 2031-2038
67. Sozer S, Fiel M I., Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009 113 (21) 5246-5249
68. Hoekstra J, Leebeek F W., Plessier A et al, European Network for Vascular Disorders of the Liver. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 2009 51 (4) 696-706
69. Ho V T., Linden E, Revta C, Richardson P G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007 33 (4) 373-388
70. DeLeve L D. Hepatic microvasculature in liver injury. Semin Liver Dis 2007 27 (4) 390-400
71. Tichelli A, Gratwohl A. Vascular endothelium as novel target of graft-versus-host disease. Best Pract Res Clin Haematol 2008 21 (2) 139-148
72. Cooke K R., Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008 14 (1, suppl 1) 23-32
73. Richardson P G., Murakami C, Jin Z et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002 100 (13) 4337-4343
74. Witlin A G., Sibai B M. Postpartum ovarian vein thrombosis after vaginal delivery: a report of 11 cases. Obstet Gynecol 1995 85 (5 Pt 1) 775-780
75. Heavrin B S., Wrenn K. Ovarian vein thrombosis: a rare cause of abdominal pain outside the peripartum period. J Emerg Med 2008 34 (1) 67-69
76. Cole M S., Minifee P K., Wolma F J. Coumarin necrosisa review of the literature. Surgery 1988 103 (3) 271-277
77. Kipen C S. Gangrane of the breasta complication of anticoagulant therapy. Report of two cases. N Engl J Med 1961 265 638-640
78. Chan Y C., Valenti D, Mansfield A O., Stansby G. Warfarin induced skin necrosis. Br J Surg 2000 87 (3) 266-272
79. Becker C G. Oral anticoagulant therapy and skin necrosis: speculations on pathogenesis. Adv Exp Med Biol 1987 214 217-222
80. Rose V L., Kwaan H C., Williamson K, Hoppensteadt D, Walenga J, Fareed J. Protein C antigen deficiency and warfarin necrosis. Am J Clin Pathol 1986 86 (5) 653-655
81. Vigano D'Angelo S, Comp P C., Esmon C T., D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986 77 (2) 416-425
82. Kelton J G., Warkentin T E. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008 112 (7) 2607-2616
83. Kwaan H C., Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia. Semin Thromb Hemost 1999 25 (suppl 1) 23-27
84. Blank M, Shoenfeld Y, Tavor S et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002 14 (2) 121-129
85. Sadler J E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008 112 (1) 11-18
86. Kwaan H C., Boggio L N. The clinical spectrum of thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2005 31 (6) 673-680
87. Kwaan H C. Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge. Semin Thromb Hemost 2005 31 (6) 615-624
88. Tsai H M. Molecular mechanisms in thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2004 30 (5) 549-557
89. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombi of terminal arterioles and capillaries: an undescribed disease. Proc NY Path Soc 1924 24 21-24
90. Moake J L., Rudy C K., Troll J H. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 307 (23) 1432-1435
91. Mitra D, Jaffe E A., Weksler B, Hajjar K A., Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997 89 (4) 1224-1234
92. Stefanescu R, Bassett D, Modarresi R, Santiago F, Fakruddin M, Laurence J. Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood 2008 112 (2) 340-349
93. Kwaan H C. Endothelial cells are not all alike. Blood 2008 112 (2) 218
94. Ruiz-Torres M P., Casiraghi F, Galbusera M et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005 93 (3) 443-452
95. Zimmerhackl L B., Besbas N, Jungraithmayr T et al, European Study Group for Haemolytic Uraemic Syndromes and Related Disorders. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006 32 (2) 113-120
96. Karch H, Friedrich A W., Gerber A, Zimmerhackl L B., Schmidt M A., Bielaszewska M. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. Semin Thromb Hemost 2006 32 (2) 105-112
97. Obrig T G., Del Vecchio P J., Brown J E. et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988 56 (9) 2373-2378
98. Obrig T G., Louise C B., Lingwood C A., Boyd B, Barley-Maloney L, Daniel T O. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993 268 (21) 15484-15488
99. Fujii J, Wood K, Matsuda F et al. Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein. Infect Immun 2008 76 (8) 3679-3689
100. Cervera R, Khamashta M A., Shoenfeld Y et al, Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009 68 (9) 1428-1432
101. Ruch J, McMahon B, Ramsey G, Kwaan H C. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am J Hematol 2009 84 (2) 120-122
102. Francischetti I M., Seydel K B., Monteiro R Q. Blood coagulation, inflammation, and malaria. Microcirculation 2008 15 (2) 81-107
103. Michiels J J., Berneman Z N., Schroyens W, Van Vliet H H. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004 15 (2) 67-84
104. Franchini M, Mannucci P M. Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med 2008 19 (7) 476-481
105. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003 348 (15) 1435-1441
106. Prandoni P. Venous and arterial thrombosis: two aspects of the same disease? Eur J Intern Med 2009 20 (6) 660-661
107. Ageno W, Prandoni P, Romualdi E et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006 4 (9) 1914-1918
108. Ay C, Tengler T, Vormittag R et al. Venous thromboembolisma manifestation of the metabolic syndrome. Haematologica 2007 92 (3) 374-380
109. Hansson P O., Eriksson H, Welin L, Svärdsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: the study of men born in 1913. Arch Intern Med 1999 159 (16) 1886-1890
110. Goldhaber S Z., Grodstein F, Stampfer M J. et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997 277 (8) 642-645 (Pubitemid 27097428)
111. Vayá A, Mira Y, Ferrando F et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002 118 (1) 255-259
112. Marcucci R, Liotta A A., Cellai A P. et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 2003 115 (8) 601-605
113. Khawaja F J., Kullo I J. Novel markers of peripheral arterial disease. Vasc Med 2009 14 (4) 381-392
114. Ariesen M J., Claus S P., Rinkel G J., Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003 34 (8) 2060-2065
115. Johansson L, Jansson J H., Stegmayr B, Nilsson T K., Hallmans G, Boman K. Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. Stroke 2004 35 (4) 826-830
116. Naidech A M., Bernstein R A., Levasseur K et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 2009 65 (3) 352-356
117. Stein E, McMahon B, Kwaan H, Altman J K., Frankfurt O, Tallman M S. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009 22 (1) 153-163
118. Kwaan H C., Wang J, Boggio L N. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2002 20 (1) 33-41
119. Tallman M S., Hakimian D, Kwaan H C., Rickles F R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leuk Lymphoma 1993 11 (12) 27-36
120. Tallman M S., Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992 79 (3) 543-553
121. Di Bona E, Avvisati G, Castaman G et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000 108 (4) 689-695
122. de la Serna J, Montesinos P, Vellenga E et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008 111 (7) 3395-3402
123. Tallman M S., Lefèbvre P, Baine R M. et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004 2 (8) 1341-1350
124. Menell J S., Cesarman G M., Jacovina A T., McLaughlin M A., Lev E A., Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999 340 (13) 994-1004
125. Kwaan H C., Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost 2004 2 (2) 306-312
126. Sanz M A., Montesinos P, Vellenga E et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008 112 (8) 3130-3134
127. Athale U H., Chan A K. Hemorrhagic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007 33 (4) 408-415
128. Slats A M., Egeler R M., van der Does-van den Berg A et al. Causes of deathother than progressive leukemiain childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005 19 (4) 537-544
129. Goldhaber S Z., Bounameaux H. Thrombolytic therapy in pulmonary embolism. Semin Vasc Med 2001 1 (2) 213-220
130. Kanter D S., Mikkola K M., Patel S R., Parker J A., Goldhaber S Z. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997 111 (5) 1241-1245
131. Huynh T, Cox J L., Massel D et al, FASTRAK II Network. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J 2004 148 (1) 86-91
132. Micieli G, Marcheselli S, Tosi P A. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag 2009 5 (1) 397-409
133. Ribo M, Montaner J, Molina C A. et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004 35 (9) 2123-2127 (Pubitemid 39129572)
134. Lansberg M G., Albers G W., Wijman C A. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007 24 (1) 1-10
135. Raanani P, Segal E, Levi I et al. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRAa manifestation of the basic disease or the treatment. Leuk Lymphoma 2000 37 (5-6) 605-610
136. Vella A, Nippoldt T B., Morris J C. III. Adrenal hemorrhage: a 25-year experience at the Mayo Clinic. Mayo Clin Proc 2001 76 (2) 161-168
137. Rao R H., Vagnucci A H., Amico J A. Bilateral massive adrenal hemorrhage: early recognition and treatment. Ann Intern Med 1989 110 (3) 227-235
138. Zissin R, Gayer G, Kots E, Ellis M, Bartal G, Griton I. Transcatheter arterial embolisation in anticoagulant-related haematomaa current therapeutic option: a report of four patients and review of the literature. Int J Clin Pract 2007 61 (8) 1321-1327
139. Campbell N R., Hull R D., Brant R, Hogan D B., Pineo G F., Raskob G E. Aging and heparin-related bleeding. Arch Intern Med 1996 156 (8) 857-860
140. Astrup T, Sjolin K E. Thromboplastic and fibrinolytic activity of human synovial membrane and fibrous capsular tissue. Proc Soc Exp Biol Med 1958 97 (4) 852-853
141. Caughey D E., Highton T C. Components of the fibrinolytic system in synovial joints. Normal bovine compared with normal and abnormal human synovial joints. Ann Rheum Dis 1967 26 (4) 297-305
142. Hollestelle M J., Thinnes T, Crain K et al. Tissue distribution of factor VIII gene expression in vivoa closer look. Thromb Haemost 2001 86 (3) 855-861
143. Yamamoto K, de Waard V, Fearns C, Loskutoff D J. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood 1998 92 (8) 2791-2801
144. Rand J H., Badimon L, Gordon R E., Uson R R., Fuster V. Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location. Arteriosclerosis 1987 7 (3) 287-291
145. Wu Q Y., Drouet L, Carrier J L. et al. Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis 1987 7 (1) 47-54
146. Bahnak B R., Wu Q Y., Coulombel L et al. Expression of von Willebrand factor in porcine vessels: heterogeneity at the level of von Willebrand factor mRNA. J Cell Physiol 1989 138 (2) 305-310
147. Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 2009 335 (1) 205-222
148. Ishii H, Salem H H., Bell C E., Laposata E A., Majerus P W. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986 67 (2) 362-365
149. Lupu C, Westmuckett A D., Peer G et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol 2005 167 (4) 1161-1172
150. Sawdey M S., Loskutoff D J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991 88 (4) 1346-1353
151. Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996 97 (11) 2440-2451 (Pubitemid 26187331)
152. Bidwell E. Fibrinolysins of human plasma; a comparison of fibrinolytic plasma from normal subjects and from cadaver blood with plasmin prepared by activation with chloroform. Biochem J 1953 55 (3) 497-506
153. Kwaan H C., McFadzean A J., Cook J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet 1956 270 (6908) 132-136
154. Kwaan H C., McFadzean A J., Cook J. On plasma fibrinolytic activity in cryptogenetic splenomegaly. Scott Med J 1957 2 (4) 137-150
155. Mackman N. On the trail of microparticles. Circ Res 2009 104 (8) 925-927
156. Morel O, Toti F, Hugel B et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006 26 (12) 2594-2604
157. Morel O, Toti F, Bakouboula B, Grunebaum L, Freyssinet J M. Procoagulant microparticles: criminal partners in atherothrombosis and deleterious cellular exchanges. Pathophysiol Haemost Thromb 2006 35 (12) 15-22
158. Burnier L, Fontana P, Kwak B R., Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009 101 (3) 439-451
159. Furie B, Furie B C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004 10 (4) 171-178
160. Thomas G M., Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009 206 (9) 1913-1927
161. Carnemolla R SV, Shuvaev V V., Muzykantov V. Targeting antioxidant and anti-thrombotic biotherapeutics to endothelium. Semin Thromb Hemost 2010 36 (3) 332-342